Vogt-Koyanagi-Harada-like Syndrome Complicating Pembrolizumab Treatment for Metastatic Melanoma - Centre de recherche en cancérologie de Lyon (UMR INSERM 1052 ; CNRS 5286 ; Centre Léon Bérard) Accéder directement au contenu
Article Dans Une Revue Journal of Immunotherapy Année : 2017

Vogt-Koyanagi-Harada-like Syndrome Complicating Pembrolizumab Treatment for Metastatic Melanoma

M. Bricout
  • Fonction : Auteur
A. Petre
  • Fonction : Auteur
M. Amini-Adle
  • Fonction : Auteur
W. Bezza
  • Fonction : Auteur
Laurent Kodjikian
S. Dalle
L. Thomas
  • Fonction : Auteur

Résumé

Vogt-Koyanagi-Harada (VKH) syndrome is a rare condition implicating systemic immune reaction against melanocytes. The pathophysiology is unclear. A genetic predisposition has been suggested as HLA-DR4/DRB1*04 is more common among VKH patients. Drug induced VKH syndrome has been reported in advanced melanoma patients receiving immunotherapy, including ipilimumab and adoptive cell transfer of Tumor-Infiltrating Lymphocyte associated with IL-2. To date, no case of anti PD-1 -induced VKH syndrome has been described. We report here the case of a HLA-DR4/DRB1*04 patient successfully treated with anti PD-1 for advanced melanoma who developed a systemic immune reaction against melanocytes for whom we discuss a VKH-like syndrome diagnosis in a potentially genetically predisposed patient

Domaines

Cancer
Fichier non déposé

Dates et versions

hal-01795713 , version 1 (18-05-2018)

Identifiants

Citer

M. Bricout, A. Petre, M. Amini-Adle, W. Bezza, Pascal Seve, et al.. Vogt-Koyanagi-Harada-like Syndrome Complicating Pembrolizumab Treatment for Metastatic Melanoma. Journal of Immunotherapy, 2017, 40 (1537-4513 (Electronic)), pp.77-82. ⟨10.1097/CJI.0000000000000154⟩. ⟨hal-01795713⟩
16 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More